Capricor Therapeutics (CAPR) Interest & Investment Income (2010 - 2026)
Capricor Therapeutics (CAPR) posted quarterly Interest & Investment Income of -$536881.0 for Q1 2026, down 173.59% year-over-year from $729542.0 in Q1 2025, and up 4.29% quarter-over-quarter from -$560968.0 in Q4 2025.
Powered by 
Analysis
Capricor Therapeutics (CAPR) Interest & Investment Income (2010 - 2026) Analysis & Trends
Capricor Therapeutics' Interest & Investment Income history runs 17 years deep, the most recent figure standing at -$536881.0 for Q1 2026.
- In Q1 2026, Interest & Investment Income fell 173.59% year-over-year to -$536881.0; the TTM figure through Mar 2026 stood at -$2.1 million (down 220.34% YoY), while the FY2025 annual figure was -$743801.0, down 133.76% from the prior year.
- Interest & Investment Income for Q1 2026 stood at -$536881.0, up from -$560968.0 in the prior quarter.
- The five-year high for Interest & Investment Income was $729542.0 in Q1 2025, with the low at -$560968.0 in Q4 2025.
- The 5-year median for Interest & Investment Income is $22830.0 (2022), against an average of $21703.6.
- The sharpest annual moves came in 2022 and 2024: Interest & Investment Income surged 2275.49% in 2022, then tumbled 280.28% in 2024.
- Capricor Therapeutics' Interest & Investment Income stood at $379699.0 in 2022, then tumbled by 67.71% to $122605.0 in 2023, then jumped by 459.99% to $686572.0 in 2024, then plunged by 181.71% to -$560968.0 in 2025, then gained by 4.29% to -$536881.0 in 2026.
- Business Quant data shows CAPR's Interest & Investment Income at -$536881.0 in Q1 2026, -$560968.0 in Q4 2025, and -$543452.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 67.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 35.58 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 27.90 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 28.14 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 5.13 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 10.98 Mn |
| 10 | Capricor Therapeutics | 543.30 Mn | 543.30 Mn | - | 2.21 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 2.21 Mn |
| Mar 31, 2026 | -536,881.00 |
| Dec 31, 2025 | 2.02 Mn |
| Sep 30, 2025 | 1.71 Mn |
| Jun 30, 2025 | 1.79 Mn |
| Mar 31, 2025 | 784,972.00 |
| Dec 31, 2024 | 686,572.00 |
| Sep 30, 2024 | 453,152.00 |
| Jun 30, 2024 | -152,714.00 |
| Mar 31, 2024 | 71,888.00 |
| Dec 31, 2023 | 452,199.00 |
| Sep 30, 2023 | 479,380.00 |
| Jun 30, 2023 | 84,707.00 |
| Mar 31, 2023 | -10,258.00 |
| Dec 31, 2022 | 379,699.00 |
| Sep 30, 2022 | 106,635.00 |
| Jun 30, 2022 | 22,830.00 |
| Mar 31, 2022 | 13,440.00 |
| Dec 31, 2021 | 15,984.00 |
| Sep 30, 2021 | 15,570.00 |